MIDA Biotech

What MIDA Biotech does

MIDA Biotech B.V. is a Dutch private biotechnology company founded in 2020 and headquartered in Amsterdam, with its R&D operations housed in the Stem Cell Innovation Laboratory at Leiden Bioscience Park. The company is a wholly-owned subsidiary of Orgenesis Inc. (NASDAQ: ORGS) and operates as Orgenesis's Western European implementation vehicle for decentralized cell and gene therapy manufacturing. MIDA's core technology is a microfluidic-based automated manufacturing platform for autologous induced pluripotent stem cells (iPSCs), complemented by two additional programs: a neurodegeneration platform targeting peripheral nerve regeneration (ALS, chemotherapy-induced neuropathy) using molecules and stem cells, and an age-related disorder platform built on an in vivo phenotyping approach for multi-organ disorders such as cardiovascular disease. Across all programs, the company intends to integrate AI and microfluidic technologies into mobile Good Manufacturing Practice (GMP) facilities to reduce cost and production time of personalized cell therapies.

The company's go-to-market is partnership-driven rather than direct. MIDA partners with Orgenesis to deploy Orgenesis Mobile Processing Units and Labs (OMPULs) at leading hospitals in Italy, Germany, Spain, and the Benelux region, enabling point-of-care development, optimization, and manufacturing of cell and gene therapies. Revenue mechanics are diversified across three streams: point-of-care services delivered through OMPUL deployments at hospitals, non-dilutive research and development grants (most notably a €4 million European Innovation Council Pathfinder Challenge Program grant awarded in May 2022 to a consortium led by MIDA), and future licensing and royalty income from jointly developed therapies with Orgenesis. Customers are segmented between hospitals and medical institutions (primary, vertical) and biotech and pharmaceutical companies (primary, business unit), with end-patients (cancer, diabetes, Parkinson's, blindness, ALS) representing the downstream demand base for the therapies in development. Pricing is project-based and not publicly disclosed, consistent with a B2B partnership model.

MIDA Biotech operates with a lean team of 1-10 employees, including a General Manager/CSO (Malin Stridh, Ph.D.), a CFO (Thom van Driel), two research scientists, and senior scientific advisors with deep iPSC and stem cell biology credentials (notably Prof. Micha Drukker). The company's competitive positioning rests on the integration of AI-enabled microfluidic manufacturing with a regulatory-compliant mobile GMP infrastructure, anchored in the Leiden Bioscience Park talent and innovation ecosystem. As of the most recent data, the company remains pre-commercial, with growth contingent on the maturation of its iPSC manufacturing platform, expansion of OMPUL deployments, and successful progression of its therapeutic programs toward regulatory milestones.

Name

MIDA Biotech

Legal name

MIDA Biotech B.V.

Website

https://midabiotech.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

MIDA Biotech B.V. is a Dutch subsidiary of Orgenesis Inc. that develops microfluidic, AI-integrated manufacturing of autologous iPSCs and related stem cell therapies, deploying mobile GMP units at Western European hospitals through the Orgenesis POCare network.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell therapy
• Cell therapy manufacturing
• Regenerative medicine
• Personalized cell therapy
• Point of care biotech

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Point of Care Services: Revenue generated through deployment of OMPULs at hospitals and medical institutions for onsite cell and gene therapy development and manufacturing. Services include development, optimization, and manufacturing of personalized therapies at point of care.
2. Research and Development Grants: Government and institutional funding for advanced production technologies for autologous iPSCs, including the 4-million-euro European Innovation Council Pathfinder Challenge Program grant.
3. Therapeutics Development and Licensing: Development of cell and gene therapies and immunotherapies through collaboration with Orgenesis, targeting commercialization through regulatory approval pathways.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

MIDA Biotech develops stem cell-based therapies and manufacturing technologies, including automated microfluidic production of personalized induced pluripotent stem cells (iPSCs), neurodegenerative disease treatments targeting damaged motor and sensory nerves, and age-related disorder therapies using an in vivo phenotyping platform. Through its partnership with Orgenesis, the company also deploys Mobile Processing Units and Labs (OMPULs) at hospitals for point-of-care cell and gene therapy manufacturing.

Product overview

MIDA Biotech is an innovation company offering a multi-platform approach to stem cell therapy and personalized medicine. The company operates three core technology platforms: (1) Stem Cell Manufacturing using microfluidic technology for automated production of personalized iPS cells, (2) Neurodegenerative Disease Programs developing molecules and stem cells to recover damaged motor and sensory nerves, and (3) Age-Related Disorder Therapies using an in vivo phenotyping platform. The company also partners with Orgenesis to deploy OMPULs (Mobile Processing Units and Labs) at hospitals for point-of-care cell and gene therapy development.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Manufacturing Platform Automated manufacturing platform using microfluidic technology to produce personalized induced pluripotent stem cells (iPSCs) for autologous cell grafts and tissue replacement therapies; designed for hospitals and biotech companies developing personalized medicine.
• Neurodegenerative Disease Program Research and development program using proprietary molecules and stem cells to regenerate damaged peripheral neurons, including motor and sensory nerves, targeting conditions such as ALS and chemotherapy-induced nerve damage.
• Age-Related Disorder Therapy Platform In vivo phenotyping platform for identifying compounds that promote tissue health and counteract multi-organ disorders such as cardiovascular disease, with the goal of extending human health span.
• OMPULs (Orgenesis Mobile Processing Units and Labs) Multi-purpose, mobile, autonomous Good Manufacturing Practice (GMP) facilities deployed at hospitals for onsite development, optimization, and manufacturing of cell and gene therapies at the point of care, developed in partnership with Orgenesis Inc.

Quantifiable outcome

• Reduction in costs and production time for personalized iPS cells for cancer immunotherapies and regenerative medicine
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Orgenesis Inc. (NASDAQ: ORGS)coreStrategic or Co-development PartnerMIDA Biotech partners with Orgenesis to establish Point of Care (POCare) centers at hospitals and medical institutions in Western Europe. The collaboration includes deployment of Mobile Processing Units and Labs (OMPULs) at leading hospitals in Italy, Germany, Spain, and Benelux. Activities include joint research, development, and validation for cell and gene therapies, with focus on scaling through to commercialization with regulatory compliance and governmental approval standards.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Orgenesis Inc. NASDAQ-listed parent company (ORGS) of MIDA Biotech and operator of the POCare network deploying OMPULs at hospitals. Directly comparable as the parent platform through which MIDA's technology is commercialized in Western Europe.
• Lonza Group: Global contract development and manufacturing organization (CDMO) with established cell and gene therapy manufacturing services, including autologous and iPSC-derived processes. Comparable as an incumbent cell therapy manufacturing infrastructure provider whose centralized approach contrasts with MIDA's decentralized OMPUL model.

Direct peers

• BlueRock Therapeutics: Bayer-owned clinical-stage cell therapy company developing iPSC-derived cell therapies, including dopaminergic neuron programs for Parkinson's disease. Directly comparable as an iPSC-derived regenerative medicine developer pursuing similar therapeutic indications.
• Fate Therapeutics: Clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell cancer immunotherapies. Comparable as an iPSC platform cell therapy developer focused on cancer immunotherapy and regenerative applications.
• Century Therapeutics: Clinical-stage company developing allogeneic iPSC-derived cell therapies for cancer and autoimmune diseases. Comparable as a direct iPSC-derived cell therapy competitor advancing multi-platform programs.

Emerging players

• bit.bio: UK-based company developing iPSC reprogramming and deterministic differentiation technology for cell therapy applications. Comparable as an iPSC manufacturing platform developer targeting cell therapy economics.
• TreeFrog Therapeutics: French biotech with proprietary iPSC manufacturing technology (C-Stem) using microfluidic encapsulation to scale and reduce cost of cell therapy production. Directly comparable as a microfluidic iPSC manufacturing platform peer.
• Cynata Therapeutics: Australian clinical-stage company developing mesenchymal stem cell (MSC) therapies manufactured using a proprietary platform technology. Comparable as a stem cell therapy developer with platform manufacturing focus.
• Pluri (formerly Pluristem): Israeli cell therapy company developing placenta-derived cell therapies for inflammatory, ischemic, and hematologic conditions. Comparable as a placental/cell-based therapy developer using scalable manufacturing platforms.
• Aspen Neuroscience: US-based clinical-stage company developing autologous iPSC-derived dopaminergic neuron replacement therapy for Parkinson's disease. Directly comparable for iPSC-derived neuronal cell therapy targeting neurodegenerative disease.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIDA Biotech